SCNX Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Scienture Holdings, Inc. had $0.4M of revenue in fiscal 2025, up 216.0% on the year before. Over five years, revenue changed β52.1% a year on average.
Last close Β· Oct 23, 2026
$2.88
4.0%Hi! I read Scienture Holdings, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+216.0%
Yes. Sales grew 216.0% last year.
Does it make a profit?
β9,618.2%
No. It lost money last year.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Scienture Holdings, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 11, 2026
Wednesday Β· in 16 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Oct 13, 2026 | Period ended Sep 30, 2026 | Time not announced | 8-K β |
| Aug 13, 2026 | Q2 '26 | After the market closes | 10-Q β |
| May 15, 2026 | Q1 '26 | After the market closes | 10-Q β |
| Mar 30, 2026 | Q4 '25 | Before the market opens | 10-K β |
| Nov 12, 2025 | Q3 '25 | After the market closes | 10-Q β |
| Aug 12, 2025 | Q2 '25 | Before the market opens | 10-Q β |
| May 12, 2025 | Q1 '25 | After the market closes | 10-Q β |
| Mar 26, 2025 | Q4 '24 | Time not announced | 10-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Scienture Holdings, Inc. had $0.4M of revenue in fiscal 2025, up 216.0% on the year before. Over five years, revenue changed β52.1% a year on average. Its operating margin was β9,868.1%, up 894.0Β pts: of every 100 in sales, about β9,868 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Scienture Holdings, Inc. lost $41.5M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Scienture Holdings, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $3.1M | $1.1M | $0.0M | $0.3M | $6.7M |
| Debt incl. finance leases | β | β | β | $2.9M | β |
| Debt / equity | β | β | β | 0.0x | β |
| Interest coverage | β224.3x | β8.7x | β3.7x | β11.0x | β10.4x |
| Current ratio | 4.7x | 1.0x | 0.2x | 0.8x | 2.9x |
| Quick ratio | 4.7x | 0.9x | 0.2x | 0.8x | 2.8x |
| Total assets | $5.8M | $3.7M | $12.5M | $105M | $84.2M |
| Total liabilities | $2.0M | $3.4M | $12.0M | $25.8M | $14.1M |
| Shareholders' equity | $3.8M | $0.8M | $0.5M | $79.1M | $70.1M |
| Net debt (β = net cash) | β | β | β | $2.6M | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Scienture Holdings, Inc. passes 4 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 8 | 6 / 9 | 4 / 9 | 3 / 8 | 2 / 8 | 4 / 8 | 1 / 8 | 4 / 8 | 4 / 8 |
| Accruals ratio | β669.4% | 24.6% | β18.6% | β10.9% | β4.2% | β35.3% | β41.1% | β192.3% | 39.8% | β29.8% |
| Altman Z'' | β124.35 | β38.05 | β9.71 | 2.14 | 8.44 | β9.45 | β22.47 | β15.57 | 0.96 | β0.88 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $2.5M | $2.9M | $3.8M | $7.4M | $17.1M | $9.9M | $10.3M | $1.4M | $0.1M | $0.4M |
| Gross profit | $2.5M | $2.9M | $3.4M | $4.9M | $5.7M | $4.7M | $5.5M | $0.0M | $0.0M | $0.3M |
| Research and development | β | β | β | β | β | β | β | β | $2.2M | $2.0M |
| Operating income | β$1.0M | $0.4M | β$0.1M | $0.1M | β$2.5M | β$5.3M | β$2.9M | β$4.4M | β$14.7M | β$42.6M |
| Interest expense | $0.2M | $0.2M | $0.1M | $0.1M | $0.0M | $0.0M | $0.3M | $1.2M | $1.3M | $4.1M |
| Pretax income | β | β | β | β | β | β | β | β$8.5M | β$18.8M | β$43.5M |
| Income tax | β | β | β | β | β | β | β | β | β$0.5M | β$2.0M |
| Net income | β$2.8M | $0.3M | $0.0M | β$0.3M | β$2.5M | β$5.3M | β$3.5M | β$17.8M | $9.1M | β$41.5M |
| Net income to common | β | β | β | β | β$2.5M | β$5.3M | β$3.5M | β | β | β |
| Diluted EPS | β$0.09 | $0.01 | $0.00 | β$0.05 | β$0.33 | β$0.65 | β$6.13 | β$23.35 | $2.48 | β$2.70 |
| Diluted shares | 0.03B | 0.03B | 0.01B | 0.01B | 0.01B | 0.01B | 0.00B | 0.00B | 0.00B | 0.02B |
| Cash flow | ||||||||||
| Cash from operations | β$0.5M | $0.2M | $0.3M | $0.1M | β$2.2M | β$2.6M | β$1.5M | β$2.2M | β$14.3M | β$13.4M |
| Capital expenditure | β | β | β | β | $0.0M | $0.0M | β | β | $0.0M | β |
| Free cash flow | β | β | β | β | β$2.3M | β$2.6M | β | β | β$14.3M | β |
| Depreciation and amortization | $0.0M | $0.0M | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.5M |
| Stock-based compensation | β | β | β | $0.2M | $0.4M | $0.1M | $0.1M | $0.0M | $0.0M | $2.1M |
| Dividends paid | β | β | β | β | β | β | β | β | $14.9M | β |
| Dividends and buybacks | β | β | β | β | β | β | β | β | $14.9M | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $0.0M | $0.2M | $0.9M | $2.9M | $5.9M | $3.1M | $1.1M | $0.0M | $0.3M | $6.7M |
| Total debt | β | $0.7M | $0.5M | $0.2M | β | β | β | β | $2.9M | β |
| Deposits | β | β | β | β | β | β | β | β | β | $1.2M |
| Current assets | $0.3M | $0.6M | $1.5M | $3.8M | $9.2M | $4.4M | $2.1M | $2.8M | $6.3M | $7.9M |
| Current liabilities | $1.5M | $0.5M | $0.9M | $0.5M | $0.8M | $0.9M | $2.1M | $11.6M | $7.9M | $2.7M |
| Inventory | β | β | $0.1M | $0.1M | $1.3M | $0.1M | $0.1M | $0.0M | β | $0.2M |
| Property and equipment, net | β | β | $0.0M | $0.2M | $0.2M | $0.1M | $0.1M | $0.0M | $0.0M | $0.0M |
| Goodwill | β | β | $0.7M | $0.7M | β | $0.0M | $0.0M | β | $21.4M | β |
| Intangible assets | β | β | β | β | β | β | β | $9.0M | $76.4M | $71.0M |
| Total assets | $0.3M | $0.6M | $2.2M | $5.6M | $9.8M | $5.8M | $3.7M | $12.5M | $105M | $84.2M |
| Total liabilities | $1.5M | $0.9M | $1.4M | $1.4M | $1.1M | $2.0M | $3.4M | $12.0M | $25.8M | $14.1M |
| Preferred stock | $0.0M | $0.0M | β | β | β | β | β | β | β | β |
| Shareholders' equity | β$1.1M | β$0.3M | $0.8M | $4.1M | $8.7M | $3.8M | $0.8M | $0.5M | $79.1M | $70.1M |
| Margins | ||||||||||
| Gross margin | 100.0% | 100.0% | 88.3% | 65.5% | 33.3% | 48.0% | 53.8% | 3.6% | 4.4% | 76.8% |
| Operating margin | β40.6% | 13.5% | β2.3% | 1.7% | β14.6% | β53.5% | β28.4% | β322.4% | β10,762.1% | β9,868.1% |
| EBITDA margin | β40.6% | 13.9% | β | 1.8% | β14.6% | β53.4% | β28.3% | β320.9% | β10,760.6% | β9,754.2% |
| Net margin | β111.2% | 9.9% | 0.2% | β3.8% | β14.8% | β53.8% | β33.9% | β1,308.4% | 6,636.7% | β9,618.2% |
| FCF margin | β | β | β | β | β13.2% | β26.2% | β | β | β10,451.8% | β |
| Returns | ||||||||||
| Return on capital | β | 182.9% | β13.9% | 6.6% | β | β | β | β | β14.2% | β |
| Return on capital employed | 88.6% | 429.0% | β6.4% | 2.5% | β28.0% | β109.3% | β186.5% | β450.2% | β15.2% | β52.3% |
| Return on equity | β | β | 3.4% | β11.4% | β39.6% | β85.4% | β153.2% | β2,733.6% | 22.8% | β55.6% |
| Return on assets | β818.8% | 60.5% | 0.6% | β7.3% | β33.0% | β68.3% | β73.3% | β219.7% | 15.4% | β43.9% |
| Return on tangible equity | β | β | 7.6% | β8.3% | β29.2% | β141.0% | β455.0% | β | β | β |
| Growth | ||||||||||
| Revenue growth | β | 18.1% | 30.7% | 94.1% | 130.3% | β42.2% | 3.6% | β86.7% | β90.0% | 216.0% |
| Net income growth | β | β | β96.9% | β3,260.0% | β | β | β | β | β | β557.9% |
| EPS growth | β | β | β100.0% | β | β | β | β | β | β | β208.9% |
| Share count change | β | 8.1% | β82.9% | 1.8% | 30.0% | 5.6% | β93.0% | 320.3% | 53.4% | 320.1% |
| Financial health | ||||||||||
| Net debt / EBITDA | β | 1.2x | β | β20.3x | β | β | β | β | β | β |
| Debt / equity | β | β | 0.6x | 0.1x | β | β | β | β | 0.0x | β |
| Interest coverage | β6.6x | 2.5x | β1.5x | 2.4x | β85.3x | β224.3x | β8.7x | β3.7x | β11.0x | β10.4x |
| Current ratio | 0.2x | 1.2x | 1.7x | 7.3x | 10.9x | 4.7x | 1.0x | 0.2x | 0.8x | 2.9x |
| Quick ratio | 0.2x | 1.2x | 1.6x | 7.2x | 9.5x | 4.7x | 0.9x | 0.2x | 0.8x | 2.8x |
| Capital allocation | ||||||||||
| Capex / revenue | β | β | β | β | 0.2% | 0.2% | β | β | 8.8% | β |
| Stock comp / revenue | β | β | β | 2.4% | 2.6% | 0.6% | 0.8% | 2.2% | 18.7% | 479.4% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 4.0 | 6.0 | 4.0 | 3.0 | 2.0 | 4.0 | 1.0 | 4.0 | 4.0 |
| Altman Z'' | β124.3 | β38.0 | β9.7 | 2.1 | 8.4 | β9.4 | β22.5 | β15.6 | 1.0 | β0.9 |
| Accruals ratio | β669.4% | 24.6% | β18.6% | β10.9% | β4.2% | β35.3% | β41.1% | β192.3% | 39.8% | β29.8% |
Source: SEC EDGAR XBRL filings (CIK 0001382574). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
